Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688978 | 0.97 | TBXAS1 (0.46) | TBXAS1GRM5FFAR1HTR2CSMN1; SMN2 | |
| SCHEMBL689731 | 0.82 | LMNA (0.44) | TBXAS1SMN1; SMN2NPC1POLBMAPK1 | |
| SCHEMBL689235 | 0.81 | LMNA (0.44) | TBXAS1GRM5FFAR1NPC1POLB | |
| SCHEMBL689324 | 0.81 | LOXL2 (0.36) | SMN1; SMN2NPC1POLBMAPK1RAB9A | |
| SCHEMBL689402 | 0.79 | GABRG2 (0.47) | GRM5FFAR1MAPK1 | |
| SCHEMBL12750184 | 0.78 | TBXAS1 (0.55) | TBXAS1FFAR1HTR2CICMT | |
| SCHEMBL688443 | 0.77 | LOXL2 (0.35) | SMN1; SMN2 | |
| SCHEMBL12750283 | 0.75 | TBXAS1 (0.54) | TBXAS1FFAR1HTR2CICMT | |
| SCHEMBL688992 | 0.72 | GABRG2 (0.43) | GRM5FFAR1MAPK1 | |
| SCHEMBL20552139 | 0.70 | TBXAS1 (0.55) | TBXAS1PPARGSMN1; SMN2MAPK1ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | TBXAS1 383/4885GRM5 3215/4885FFAR1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.